News

Alexza and Teva also plan to restructure the obligations under the outstanding note from Teva. Alexza and Teva are working on a transition agreement to continue product availability

In October 2013, Warner Chilcott plc, Warner Chilcott Sales’ indirect parent corporation, became a wholly-owned subsidiary of Actavis plc. In March 2015, Actavis plc completed an acquisition of

Chaudhuri will report to Rajiv Malik, president of Mylan. Chaudhuri joins Mylan from GlaxoSmithKline (GSK) Consumer Healthcare, where he served for nearly three decades, and brings to Mylan

The other investors in PrEP Biopharm include Johnson & Johnson Innovation – JJDC and US-based angel investors. hVIVO will acquire a significant interest in PrEP Biopharm for £14m,

The three-year collaboration builds on the framework the companies have developed under a cancer metabolism partnership, which started in 2013. Merck and Selvita will contribute funding and resources

Earlier this year, Isis signed a license agreement with Bayer HealthCare for the development and commercialization of ISIS-FXIRx to prevent clotting disorders. Upon completion of ongoing activities at

Pexidartinib is an investigational novel, oral small molecule that selectively inhibits a primary growth driver of abnormal cells in the synovium that causes TGCT called colony stimulating factor-1

It is the fifth indication for Eylea, which is a vascular endothelial growth factor (VEGF) inhibitor formulated as an injection for the eye. Bayer is co-developing Eylea with

These findings are a step forward in the development of targeted therapies for hard-to-treat cancers. The American Cancer Society estimates that in 2015, about 21,290 new cases of